Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds
A Multicenter, International, Prospective, Randomized, Vehicle Controlled, Assessor Blinded Study Performed in Subjects With Hard to Heal Wounds, to Evaluate the Efficacy and Safety of Enzymatic Debridement With EscharEx
Sponsor: MediWound Ltd
This PHASE2 trial investigates Diabetic Lower Extremity Ulcers and Hard to Heal Wounds and is currently completed. MediWound Ltd leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MediWound Ltd
For direct contact, visit the study record on ClinicalTrials.gov .